Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ricolinostat + bortezomib + dexamethasone
- Development stage
- Unknown
- Lead developer
- Regenacy Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral (ricolinostat, Dexamethasone), Intravenous (bortezomib), Subcutaneous (bortezomib, Alternative)
01
Overview
This is a combination therapy consisting of **ricolinostat**, a selective histone deacetylase 6 (HDAC6) inhibitor; **bortezomib**, a small-molecule proteasome inhibitor; and **dexamethasone**, a synthetic glucocorticoid corticosteroid. Ricolinostat targets HDAC6, disrupting cell stress and autophagic pathways that confer resistance to proteasome inhibitors like bortezomib. Bortezomib inhibits proteasome-mediated degradation of proteins, inducing apoptosis in multiple myeloma (MM) cells. Dexamethasone has anti-inflammatory and cytotoxic effects on lymphoid malignancies. The combination has shown synergistic anti-myeloma activity, particularly in relapsed/refractory multiple myeloma (RRMM), and is intended to enhance overall efficacy and overcome resistance to bortezomib. Recommended phase II dosing for ricolinostat in combination is 160 mg orally once daily with manageable toxicity[1][6][8].
- Other names
- ricolinostat + bortezomib + dexamethasone
02
Targets
26S proteasomeGR (Glucocorticoid receptor)HDAC6 (Histone deacetylase 6)
Beyond the preview
Go deeper on ricolinostat + bortezomib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ricolinostat + bortezomib + dexamethasone.